These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 19277407

  • 1. Plasma free tissue factor pathway inhibitor (TFPI) levels and TF-induced thrombin generation ex vivo in men with low testosterone levels.
    Agledahl I, Brodin E, Svartberg J, Hansen JB.
    Thromb Haemost; 2009 Mar; 101(3):471-7. PubMed ID: 19277407
    [Abstract] [Full Text] [Related]

  • 2. Impact of long-term testosterone treatment on plasma levels of free TFPI and TF-induced thrombin generation ex vivo in elderly men with low testosterone levels.
    Agledahl I, Brodin E, Svartberg J, Hansen JB.
    Thromb Haemost; 2009 Nov; 102(5):945-50. PubMed ID: 19888533
    [Abstract] [Full Text] [Related]

  • 3. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients.
    Falciani M, Gori AM, Fedi S, Chiarugi L, Simonetti I, Dabizzi RP, Prisco D, Pepe G, Abbate R, Gensini GF, Neri Serneri GG.
    Thromb Haemost; 1998 Mar; 79(3):495-9. PubMed ID: 9531029
    [Abstract] [Full Text] [Related]

  • 4. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: role of tissue factor pathway inhibitor.
    Kojima T, Gando S, Kemmotsu O, Mashio H, Goda Y, Kawahigashi H, Watanabe N.
    J Cardiothorac Vasc Anesth; 2001 Feb; 15(1):60-4. PubMed ID: 11254842
    [Abstract] [Full Text] [Related]

  • 5. Plasma tissue factor and tissue factor pathway inhibitor levels in patients with disseminated intravascular coagulation.
    Shimura M, Wada H, Wakita Y, Nakase T, Hiyoyama K, Nagaya S, Mori Y, Shiku H.
    Am J Hematol; 1996 Jul; 52(3):165-70. PubMed ID: 8756081
    [Abstract] [Full Text] [Related]

  • 6. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration.
    Gori AM, Pepe G, Attanasio M, Falciani M, Abbate R, Prisco D, Fedi S, Giusti B, Brunelli T, Giusti B, Brunelli T, Comeglio P, Gensini GF, Neri Serneri GG.
    Thromb Haemost; 1999 Apr; 81(4):589-93. PubMed ID: 10235445
    [Abstract] [Full Text] [Related]

  • 7. Anti-tissue factor pathway inhibitor activity in subjects with antiphospholipid syndrome is associated with increased thrombin generation.
    Adams M, Breckler L, Stevens P, Thom J, Baker R, Oostryck R.
    Haematologica; 2004 Aug; 89(8):985-90. PubMed ID: 15339683
    [Abstract] [Full Text] [Related]

  • 8. Tissue factor, tissue pathway factor inhibitor and risk factors of atherosclerosis in patients with chronic limbs ischemia: preliminary study.
    Gosk-Bierska I, Wysokin Ski W, Karnicki K, Adamiec R.
    Int Angiol; 2008 Aug; 27(4):296-301. PubMed ID: 18677291
    [Abstract] [Full Text] [Related]

  • 9. Thrombin generation in vitro and in vivo, and disturbed tissue factor regulation in patients with acute pancreatitis.
    Lindström OK, Tukiainen EM, Kylänpää ML, Mentula PJ, Puolakkainen PA, Wartiovaara-Kautto UM, Repo H, Petäjä JM.
    Pancreatology; 2011 Aug; 11(6):557-66. PubMed ID: 22213026
    [Abstract] [Full Text] [Related]

  • 10. Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasmas from patients with lupus anticoagulants.
    Liestøl S, Sandset PM, Jacobsen EM, Mowinckel MC, Wisløff F.
    Br J Haematol; 2007 Jan; 136(1):131-7. PubMed ID: 17092306
    [Abstract] [Full Text] [Related]

  • 11. Regulation of thrombin generation by TFPI in plasma without and with heparin.
    Brodin E, Appelbom H, Osterud B, Hilden I, Petersen LC, Hansen JB.
    Transl Res; 2009 Mar; 153(3):124-31. PubMed ID: 19218095
    [Abstract] [Full Text] [Related]

  • 12. [Analysis of behaviors of plasma tissue factor and tissue factor pathway inhibitor in patients with various diseases].
    Saito M, Morishita E, Asakura H, Jokaji H, Uotani C, Kumabashiri I, Yamazaki M, Aoshima K, Matsuda T.
    Rinsho Ketsueki; 1996 Sep; 37(9):794-8. PubMed ID: 8914465
    [Abstract] [Full Text] [Related]

  • 13. Tissue factor pathway inhibitor (TFPI) levels in the plasma and urine of children with meningococcal disease.
    Eling M, Stephens AC, Oragui EE, Rivers RP, Levin M.
    Thromb Haemost; 2001 Feb; 85(2):240-4. PubMed ID: 11246540
    [Abstract] [Full Text] [Related]

  • 14. Impaired control of the tissue factor pathway of blood coagulation in systemic lupus erythematosus.
    Adams MJ, Palatinus AA, Harvey AM, Khalafallah AA.
    Lupus; 2011 Dec; 20(14):1474-83. PubMed ID: 21993387
    [Abstract] [Full Text] [Related]

  • 15. Acute release of tissue factor pathway inhibitor after in vivo thrombin generation in baboons.
    Lupu C, Kruithof EK, Kakkar VV, Lupu F.
    Thromb Haemost; 1999 Dec; 82(6):1652-8. PubMed ID: 10613651
    [Abstract] [Full Text] [Related]

  • 16. Plasma tissue factor and tissue factor pathway inhibitor in patients with primary glomerulonephritis.
    Lizakowski S, Zdrojewski Z, Jagodzinski P, Rutkowski B.
    Scand J Urol Nephrol; 2007 Dec; 41(3):237-42. PubMed ID: 17469034
    [Abstract] [Full Text] [Related]

  • 17. Anticoagulant versus amidolytic activity of tissue factor pathway inhibitor in coronary artery disease.
    Mukherjee M, Ranlall N, Patel G, Rutlin A, Jehanli A, Kakkar VV.
    Blood Coagul Fibrinolysis; 2000 Apr; 11(3):285-91. PubMed ID: 10870809
    [Abstract] [Full Text] [Related]

  • 18. Atorvastatin reduces thrombin generation after percutaneous coronary intervention independent of soluble tissue factor.
    Bartok A, Steiner S, Seidinger D, Jetzl A, Huber K, Minar E, Stefenelli T, Kopp CW.
    Thromb Res; 2005 Apr; 115(6):469-74. PubMed ID: 15792677
    [Abstract] [Full Text] [Related]

  • 19. The influence of tissue factor and tissue factor pathway inhibitor polymorphisms on thrombin generation in stable coronary artery disease.
    Opstad TB, Pettersen AA, Bratseth V, Arnesen H, Seljeflot I.
    Pathophysiol Haemost Thromb; 2010 Apr; 37(2-4):98-103. PubMed ID: 21555871
    [Abstract] [Full Text] [Related]

  • 20. Tissue factor and its inhibitor in human non-crescentic glomerulonephritis--immunostaining vs plasma and urinary levels.
    Naumnik B, Borawski J, Chyczewski L, Pawlak K, Mysliwiec M.
    Nephrol Dial Transplant; 2006 Dec; 21(12):3450-7. PubMed ID: 16982632
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.